Financial Performance - For the nine months ended December 31, 2022, the total revenue was approximately HKD 40,984,000, an increase of about 2.54% compared to HKD 39,967,000 for the same period in 2021[4] - The company reported a loss attributable to owners of approximately HKD 10,077,000 for the nine months ended December 31, 2022, compared to a profit of HKD 2,729,000 for the same period in 2021, primarily due to the absence of a one-time gain from the sale of a subsidiary amounting to HKD 31,700,000[4] - For the three months ended December 31, 2022, the loss attributable to owners was approximately HKD 3,367,000, compared to a loss of HKD 4,477,000 for the same period in 2021[4] - The gross profit for the nine months ended December 31, 2022, was HKD 32,592,000, a decrease from HKD 33,558,000 in the same period of 2021[5] - The total comprehensive loss for the nine months ended December 31, 2022, was HKD 11,964,000, compared to a total comprehensive profit of HKD 9,125,000 for the same period in 2021[6] - The basic loss per share for the nine months ended December 31, 2022, was HKD (0.358), compared to earnings of HKD 0.097 per share for the same period in 2021[6] - The diluted loss per share for the three months ended December 31, 2022, was HKD (0.120), and for the nine months, it was HKD (0.358)[20] Expenses and Costs - The operating loss for the nine months ended December 31, 2022, was HKD 8,952,000, compared to an operating profit of HKD 8,352,000 for the same period in 2021[5] - The company incurred administrative expenses of HKD 36,712,000 for the nine months ended December 31, 2022, down from HKD 46,056,000 in the same period of 2021[5] - The financial costs for the nine months ended December 31, 2022, were HKD 329,000, compared to HKD 1,365,000 for the same period in 2021[5] - Selling and distribution expenses decreased by approximately 57.90% to HKD 5,528,000 for the nine months ended December 31, 2022, down from HKD 13,130,000 in the previous year, primarily due to the sale of a subsidiary[24] - Administrative expenses also saw a reduction of about 20.29%, amounting to HKD 36,712,000 for the nine months ended December 31, 2022, compared to HKD 46,056,000 in the previous year, again linked to the sale of the subsidiary[24] Dividend and Share Capital - The company did not recommend the distribution of dividends for the nine months ended December 31, 2022, consistent with the previous year[4] - The total issued share capital of the company as of December 31, 2022, is approximately HKD 29,168,000, consisting of 2,818,249,944 ordinary shares and 98,500,000 non-voting convertible preference shares[10] - No dividends were recommended for the nine months ended December 31, 2022, consistent with the previous year[30] Legal and Regulatory Matters - The company’s subsidiary, Edinburgh International Hospital Management, is involved in a lawsuit with China Merchants Hainan Development Investment Co., Ltd., seeking the return of approximately RMB 12,130,000 and additional compensation of about RMB 1,400,000[32] - The court ruling on September 6, 2022, ordered the termination of the cooperation agreement and required the return of RMB 4,900,000, which was unutilized funds previously advanced by China Merchants[34][35] - The company continues to monitor the legal proceedings and their potential impact on operations and financials[32][35] Corporate Governance - The company has complied with the corporate governance code as per GEM Listing Rules during the nine months ended December 31, 2022[53] - The audit committee has reviewed the unaudited condensed consolidated results, ensuring compliance with applicable accounting standards and GEM Listing Rules[61] - The company has established a remuneration committee to determine the remuneration packages of executive directors, considering factors such as comparable company salaries and performance-linked compensation[55] - The company has a nomination and corporate governance committee responsible for reviewing the board's structure and recommending suitable candidates for board positions[58] - The company has adopted a code of conduct for securities transactions by directors, ensuring compliance with GEM Listing Rules[52] - The company has maintained effective internal controls and risk management systems as overseen by the audit committee[59] Future Outlook - The company plans to continue evaluating the impact of COVID-19 on its operations and financial performance while monitoring related risks[28] - Future growth is expected to be supported by factors such as an aging population, increasing per capita income, and expanding health insurance coverage in China[28] - Management intends to allocate more resources to explore new opportunities and strengthen partnerships within the healthcare sector to enhance market position[28] Shareholder Information - As of December 31, 2022, the company’s director, Mr. Wu Zhihong, holds personal rights to 59,000,000 shares, representing approximately 2.09% of the total issued shares, and corporate rights to 1,581,959,460 shares, representing approximately 56.13%[38] - Major shareholder, Xingyang Global Limited, holds 1,581,959,460 shares, accounting for approximately 56.13% of the total issued shares[43] - Ms. Zheng Huiyan, as a spouse, has rights to 1,640,959,460 shares, which is about 58.22% of the total issued shares[43] - New Hope International (Hong Kong) Limited owns 343,217,539 shares, representing approximately 12.18% of the total issued shares[43] Miscellaneous - The company has relocated its registered office in the Cayman Islands effective October 1, 2022[36] - No significant events occurred after the reporting period[36] - No stock options were granted, exercised, canceled, or lapsed under the stock option plan as of December 31, 2022[47] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ended December 31, 2022[49] - There are no provisions in the company's articles of association or Cayman Islands law regarding pre-emptive rights for existing shareholders to subscribe for new shares[51] - The company has not engaged in any arrangements that would allow directors or key executives to benefit from purchasing shares or debt securities of the company or any other entity during the review period[50]
金威医疗(08143) - 2023 Q3 - 季度财报